| Autor: |
Gałązka, Jakub K., Kwiatkowska, Agnieszka, Bieńkowski, Kuba, Bielaska, Albert, Filip, Agata |
| Předmět: |
|
| Zdroj: |
Medical Research Journal (2451-2591); 2023, Vol. 8 Issue 3, p251-255, 5p |
| Abstrakt: |
Anaplastic thyroid cancer (ATC) is the rarest (1–2%) form of thyroid cancer, but also the most aggressive and associated with the worst prognosis. The survival median rate is 5–6 months, whereas only 20% of patients survive more than one year from the diagnosis, even though the usage of radiotherapy and surgical resection. The growing incidence rate of thyroid cancer and ATC determine the need for new prophylactic, diagnostic and therapeutic solutions. Metformin was first introduced as an oral antidiabetic drug. The beneficial effect of metformin on anaplastic thyroid cancer cells was confirmed, however, the mechanism of this interaction is still unclear. The usage of metformin in thyroid cancer prevention is still under discussion — nevertheless, studies conducted on larger groups support this beneficial impact, at least in patients with insulin resistance or metabolic syndrome. Both the synergistic effect of metformin in anaplastic thyroid cancer chemotherapy and its protective effect in radiotherapy are still concerns and need additional confirmation in randomized clinical trials. This review aims to sum up the recent knowledge on metformin usage in ATC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
